Pulmonx Co. (NASDAQ:LUNG) Stake Lifted by SG Americas Securities LLC

SG Americas Securities LLC increased its position in shares of Pulmonx Co. (NASDAQ:LUNG) by 27.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,555 shares of the company’s stock after purchasing an additional 3,310 shares during the period. SG Americas Securities LLC’s holdings in Pulmonx were worth $106,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in shares of Pulmonx in the 3rd quarter worth $26,000. GSA Capital Partners LLP bought a new stake in Pulmonx in the third quarter worth about $537,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Pulmonx in the third quarter worth about $480,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Pulmonx by 5.2% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,114,297 shares of the company’s stock valued at $9,238,000 after acquiring an additional 55,279 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Pulmonx by 5.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 313,169 shares of the company’s stock valued at $2,596,000 after purchasing an additional 15,543 shares in the last quarter. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Glendon E. French III sold 20,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $6.63, for a total value of $132,600.00. Following the completion of the sale, the director now directly owns 1,071,974 shares of the company’s stock, valued at $7,107,187.62. This represents a 1.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Geoffrey Beran Rose sold 4,376 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $6.18, for a total transaction of $27,043.68. Following the transaction, the insider now directly owns 291,057 shares in the company, valued at $1,798,732.26. The trade was a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,199 shares of company stock worth $208,859. Corporate insiders own 5.70% of the company’s stock.

Pulmonx Stock Up 2.6 %

LUNG stock opened at $7.01 on Thursday. The company’s 50 day simple moving average is $6.35 and its 200-day simple moving average is $6.73. Pulmonx Co. has a 52-week low of $5.46 and a 52-week high of $14.84. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The firm has a market capitalization of $276.82 million, a P/E ratio of -4.77 and a beta of 0.64.

Analysts Set New Price Targets

A number of analysts recently commented on LUNG shares. Wells Fargo & Company dropped their target price on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. Stifel Nicolaus dropped their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. Finally, Citigroup reiterated a “neutral” rating and set a $7.50 price objective (down previously from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Pulmonx currently has an average rating of “Moderate Buy” and a consensus price target of $12.75.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.